“2025 was a defining year for Orexo, one in which we resolved long standing uncertainties, made bold strategic decisions, and positioned the company for long term growth. The divestment of Zubsolv® in the US marked not just the end of an era, but the start of a more focused and future ready Orexo. With stronger financial flexibility and a clearer strategic direction, we are now better equipped to advance the AmorphOX® platform, accelerate our development programs, and deepen our impact for patients and society,”saysNikolaj Sørensen, President and CEO.

Read the full CEO statement and learn more about Orexo’s strategic agenda, the development work driven by the AmorphOX technology, as well as in‑depth financial information[1] in the Annual Report attached to this press release. The Annual Report is also available on the Company’s website at https://orexo.com/investors/.

Orexo´s sustainability report is only available on the website at https://orexo.com/who-we-are/sustainability/

For more information
Lena Wange, IR & Communications Director
Tel: +46 18 780 88 00
E-mail: ir@orexo.com

About Orexo
Orexo is a Swedish pharmaceutical company dedicated to advance treatments for severe diseases and life-saving rescue medications to meet future healthcare needs. At the core of our innovation is AmorphOX®, a proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules, enabling new approaches to route of administration, manufacturing, and distribution. With over 30 years of experience and multiple drugs approved globally, Orexo is advancing a diversified pipeline of programs in clinical and preclinical development. The company collaborates with partners in research, development, and commercialization. Headquartered in Uppsala, Sweden, Orexo is listed on Nasdaq Stockholm’s main market and trades as ADRs on the OTCQX market in the United States.

For more information about Orexo visit, www.orexo.com. You can also follow Orexo on X, LinkedIn and YouTube.

This information is information that Orexo AB (publ.) is obliged to make publicin accordance with the Securities Market Act. The information was submitted for publication at 10 am CET on March 27, 2026. 

[1] Including a breakdown of discontinued and continuing operations to reflect the effects of the sale of Zubsolv US as of December 31, 2025.

This information is information that Orexo AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-03-27 10:00 CET.

Attachments
Orexo Annual Report 2025

Läs mer på MFN